quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:50:18·525d
FDARegulatory
ClearPoint Neuro Inc. logo
PTC Therapeutics Inc. logo

November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

CLPT· ClearPoint Neuro Inc.PTCT· PTC Therapeutics Inc.
Health Care
Original source

Companies

  • CLPT
    ClearPoint Neuro Inc.
    Health Care
  • PTCT
    PTC Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 10PTCTUpdateRaymond James$108.00
  • Jan 28PTCTUpdateBarclays$119.00
  • Dec 1PTCTUpdateRBC Capital Mkts$91.00
  • Oct 20PTCTUpdateWells Fargo$73.00
  • Jun 17PTCTUpdateTruist$80.00
  • May 9PTCTUpdateBofA Securities$68.00

Related

  • INSIDER4h
    CHIEF EXECUTIVE OFFICER Klein Matthew B. sold $202,094 worth of shares (2,850 units at $70.91), decreasing direct ownership by 0.72% to 394,070 units (SEC Form 4) to satisfy withholding tax
  • SEC5h
    SEC Form DEFA14A filed by ClearPoint Neuro Inc.
  • NEWS1d
    ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
  • PR1d
    PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026
  • SEC3d
    SEC Form DEFA14A filed by PTC Therapeutics Inc.
  • SEC3d
    SEC Form DEF 14A filed by PTC Therapeutics Inc.
  • NEWS3d
    ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint
  • PR6d
    PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022